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ABSTRACT In patients with invasive fungal diseases, there is often little cellular in-
ﬂammatory response. We tested the idea that binding of the human constitutive
plasma protein serum amyloid P component (SAP) (also called PTX2) to Candida al-
bicans dampens the innate immune response to this fungus. Many pathogenic fungi
have cell surface amyloid-like structures important for adhesion and bioﬁlm forma-
tion. Human SAP bound to fungi that expressed functional cell surface amyloid, but
SAP had minimal binding to fungi with reduced expression of cell surface amyloid.
In the absence of SAP, phagocytosis of fungi by human macrophages was potenti-
ated by expression of amyloid on the fungi. SAP binding to fungi inhibited their
phagocytosis by macrophages. Macrophages pretreated with SAP displayed reduced
fungal phagocytosis, reduced secretion of inﬂammatory cytokines (IFN-, IL-6, and
TNF-), and increased secretion of the anti-inﬂammatory cytokine IL-10. SAP bound
to fungi or added to the medium upregulated the expression of the anti-
inﬂammatory receptor CD206 on macrophages. These ﬁndings suggest that SAP
bound to amyloid-like structures on fungal cells dampens the host cellular immune
response in fungal diseases such as invasive candidiasis.
IMPORTANCE Macrophages are a key part of our innate immune system and are re-
sponsible for recognizing invading microbes, ingesting them, and sending appropri-
ate signals to other immune cells. We have found that human macrophages can rec-
ognize invading yeast pathogens that have a speciﬁc molecular pattern of proteins
on their surfaces: these proteins have structures similar to the structures of amyloid
aggregates in neurodegenerative diseases like Alzheimer’s disease. However, this
surface pattern also causes the fungi to bind a serum protein called serum amyloid
P component (SAP). In turn, the SAP-coated yeasts are poorly recognized and sel-
dom ingested by the macrophages, and the macrophages have a more tolerant and
less inﬂammatory response in the presence of SAP. Therefore, we ﬁnd that surface
structures on the yeast can alter how the macrophages react to invading microbes.
KEYWORDS SAP, cytokines, functional amyloid, innate immunity, macrophage
polarization
In humans, the pentraxin serum amyloid P component (SAP) is constitutively presentin serum (typically 30 g/ml) (1, 2). SAP binds to amyloid ﬁbrils derived from
precursors, including serum amyloid A, immunoglobulin light chain, and apolipopro-
tein A1, and also binds to pathogenic viruses (3) and bacteria (4, 5). The binding of SAP
to microorganisms may be an important factor in determining the outcome of some
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disseminated infectious diseases. For example, one report demonstrated that bacteria
to which SAP bound were not opsonized or phagocytosed efﬁciently (5). In mouse
models of disseminated infection with Escherichia coli, Streptococcus pyogenes, or
Neisseria meningitidis (all of which bound SAP), the bacteria were lethal when injected
intravenously. SAP knockout mice survived infections with similar numbers of the same
bacteria, but when SAP knockout mice were injected with microbes and human SAP,
the mice succumbed to disseminated infection (5). Thus, the presence of SAP can
increase virulence in bacterial infection models.
SAP avidly binds to amyloid and is a prominent and invariant constituent of all
extracellular amyloid deposits (6). We have proposed that SAP also binds to fungi
because of functional amyloid on fungal cell surfaces (7). Candida albicans cell surface
adhesins form amyloid-like nanodomains (8). These amyloid nanodomains form in
response to shear stress and are essential for cell-cell aggregation and bioﬁlm forma-
tion (9). The amyloid interactions are functional, in the sense that amyloid-forming
ability is an important part of adhesin activity and is evolutionarily conserved in fungal
adhesins and some bacterial adhesins (10). We previously observed SAP on fungi in
invasive Candida in human tissue and found that SAP binding to the fungi, in part,
required the presence of functional amyloid on the surfaces of fungal cells (11). We also
observed SAP on fungal surfaces in deep-seated fungal diseases, including aspergillosis,
coccidioidomycosis, and zygomycosis (12).
Polymorphonuclear leukocytes (PMNs) and macrophages are sparse in anatomic
sites of invasive candidiasis even in cases with normal or elevated white blood cell
counts (11, 13). Marked reductions of host immune cells were also seen in deep-seated
disease with Aspergillus, zygomycetes, and Coccidioides (12). Other investigators have
also noted the profound absence of host immune cells in the vicinity of invasive fungi
including aspergillosis and mucormycosis, again in spite of normal or elevated periph-
eral white blood cell counts (14–16). Thus, leucopenia alone cannot explain the lack of
cellular inﬁltrates. Pentraxin 3 and C reactive protein (CRP), two pentraxins generally
acknowledged to be proinﬂammatory, were not detected on Candida species invading
gastrointestinal tissue (13). This apparent lack of an innate immune response is remi-
niscent of the histology of extracellular amyloid deposits, with their absence of any
detectable cellular response even as the amyloid destroys organs (17). A commonality
between these conditions is SAP binding to amyloid in extracellular deposits or amyloid
on fungal surfaces.
Here we report that SAP binding to C. albicans leads to decreased phagocytosis by
human macrophages and to a less aggressive host innate cellular response. These
changes may be a molecular explanation for the histological ﬁndings of minimal
inﬂammation in invasive fungal diseases.
RESULTS
SAP binds to yeast cells in proportion to the amount of functional amyloid
expressed on the fungal surface. To elucidate SAP binding to C. albicans, yeast cells
were exposed to SAP from normal human male AB serum by incubating yeasts in serum
for 1 h (the most physiological method of providing SAP, avoiding the problem of SAP
aggregation [18]). Figure 1A shows a ﬂow cytometric proﬁle demonstrating that most
C. albicans cells bound SAP and there was minimal background ﬂuorescence. We then
compared SAP binding to C. albicans to SAP binding to nonpathogenic laboratory
strains of Saccharomyces cerevisiae. S. cerevisiae W303-1B transformed with an empty
vector (pJL1) (hereinafter, S. cerevisiae-EV) expresses low levels of endogenous amyloid,
as does a transformant that expresses the nonamyloidogenic Als5pV326N form of the C.
albicans adhesin Als5p (S. cerevisiae-Als5pV326N) (19). Heterologous expression of the
amyloidogenic adhesin Als5pWT in S. cerevisiae (S. cerevisiae-Als5pWT) causes yeast cells
to adhere and form bioﬁlms in a manner similar to that of C. albicans (20, 21). Figure 1B
shows that a median of 92% of C. albicans bound SAP. By comparison, only 18% of S.
cerevisiae-EV cells bound SAP; S. cerevisiae-Als5pV326N, 19% of cells; the amyloidogenic
S. cerevisiae-Als5pWT, 40% of cells. Thus, SAP bound to yeast cells in the order of their
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expression of cell surface amyloid: C. albicans  S. cerevisiae-Als5pWT  S. cerevisiae-
Als5pV326N or S. cerevisiae-EV.
SAP binding to C. albicans is inhibited by the calcium chelator EDTA. SAP
binding to amyloid ﬁbers is calcium dependent, and bound SAP is dissociated from
amyloid ﬁbers with EDTA (18). To determine whether SAP binding to C. albicans is also
sensitive to EDTA, we added EDTA to mixtures of serum and C. albicans. EDTA
signiﬁcantly inhibited SAP binding to the cells (Table 1) (see Fig. S1A in the supple-
mental material). These data suggest that SAP binding to C. albicans is at least partly
dependent on calcium.
Phagocytosis of fungi is dependent on expression of fungal functional amy-
loid. We investigated the phagocytosis of yeasts by human macrophages and found
that macrophages bound approximately twice as many C. albicans cells as S. cerevisiae
cells. The three S. cerevisiae strains bound in similar numbers (Fig. 1C, left). However, the
FIG 1 Binding and phagocytosis of yeasts by human macrophages. (A) SAP binding to C. albicans yeast cells determined by SAP antibody labeling and ﬂow
cytometry. (B) SAP binding to yeast cells of C. albicans, S. cerevisiae-EV, the amyloidogenic S. cerevisiae-Als5pWT, and the nonamyloidogenic, S. cerevisiae-
Als5pV326N. SAP was offered to yeasts in normal human serum. Each symbol is the average of one of seven independent experiments. (C, left) Binding of fungi
to macrophages upon the addition of C. albicans, S. cerevisiae-EV, S. cerevisiae-Als5pWT, or S. cerevisiae-Als5pV326N. (Right) Phagocytosis of the same strains of
yeast cells by macrophages. Each symbol is the average from three independent experiments. (D) Effect of SAP on macrophage binding and phagocytosis of
C. albicans. (Top left) Binding of yeast cells to control macrophages or macrophages pretreated with SAP. (Top right) Phagocytosis of C. albicans by control
macrophages or macrophages pretreated with SAP (30 g/ml). (Bottom left) Binding of yeast cells in serum-free medium and yeast cells offered SAP in normal
human serum to macrophages. (Bottom right) Phagocytosis by macrophages of yeast cells in serum-free medium and yeast cells offered SAP in normal human
serum (results of three separate experiments each with 3,200 macrophages counted/variable). Note that the y axis is 10-fold higher for phagocytosis than the
binding graphs. Statistical signiﬁcance was determined by Mann-Whitney U test and indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P  0.01; ***, P 
0.001; ****, P  0.0001. Medians are plotted to show central tendency. Bars represent 95% conﬁdence intervals.
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macrophages ingested signiﬁcantly different numbers of the yeasts (Fig. 1C, right).
Macrophages phagocytosed a median of 79 C. albicans yeast cells/50 macrophages
and 57 cells/50 macrophages for the amyloid-bearing strain S. cerevisiae-Als5pWT. In
contrast, few non-amyloid-bearing yeasts were ingested: S. cerevisiae-EV, 4 cells/50
macrophages and S. cerevisiae-Als5pV326N, 17 cells/50 macrophages. These data
suggest that the presence of yeast cell surface amyloid increases the phagocytosis
of yeast cells.
SAP treatment of macrophages inhibits macrophage phagocytosis of yeast
cells. Having shown that SAP binding to yeast cells and macrophage phagocytosis of
yeast cells are both increased by the presence of yeast surface amyloids, we investi-
gated the effect of SAP on macrophage phagocytosis of yeast cells. Human macro-
phages were incubated with or without SAP for 60 min in 96-well plates, the wells were
washed with serum-free medium, and then yeasts were added for 30 min in serum-free
medium. The SAP pretreatment led to an 3-fold increase, from 4 to 11 C. albicans
cells bound per 50 macrophages (Fig. 1D, top left), but a 86% reduction in macrophage
phagocytosis, from a median of 124 yeast cells phagocytosed/50 macrophages in
control wells (no SAP) to 17 yeast cells/50 macrophages in wells with SAP (Fig. 1D, top
right). In contrast, pretreating macrophages with the related pentraxin, C-reactive
protein (CRP) (50 g/ml) enhanced yeast phagocytosis by 16% (Fig. S1B). CRP bound to
negligible numbers of yeast cells on ﬂow cytometry (7%). SAP from Millipore contained
low concentrations of azide and EDTA; both of the additives at various concentra-
tions were incubated with macrophages to determine whether these additives
affected phagocytosis, and they did not (Fig. S1C). Furthermore, phagocytosis
results were not affected using unaltered SAP from Millipore or SAP that had been
desalted (removing any trace of azide, EDTA, and NaCl) (Fig. S1B and C). Together
these data support the hypothesis that SAP treatment of the macrophages inhibits
phagocytosis of C. albicans.
TABLE 1 Inhibition or augmentation of yeast binding of SAP and phagocytosis by human
macrophages in the presence or absence of various additivesa
Treatment
% of yeasts
binding SAP
(mean  SEM)
No. of yeasts
phagocytosed
(mean  SEM)
% inhibition or
augmentationb Signiﬁcancec
Controld 74 2
10 mM EDTA 67 2 9 0.08
25 mM EDTA 61 1 18 0.005
50 mM EDTA 53 1 28 0.001
100 mM EDTA 33 1 55 0.001
Phagocytosis, controle 136 9
100 mM mannose 30 9 78 0.001
Phagocytosis, controle 90 4
CRP 104 4 16 0.024
Phagocytosis, controle 112 9
SAP-soaked yeast 43 3 62 0.004
Phagocytosis, controlf 53 7
SAP (30 g/ml) 14 2 74 0.001
SAP ex serumg 9 1 83 0.001
aAll values are from a minimum of three independent experiments, each with a minimum of eight replicates.
bInhibition shown by negative values, and augmentation indicated by positive values.
cSigniﬁcance is for comparison of variable with macrophages only. Signiﬁcance was determined by Mann-
Whitney U test or unpaired t test.
dResults of ﬂow cytometry; serum, yeasts, and additive incubated for 1 h. See Fig. S1 in the supplemental
material for a graphical representation of the experiment.
eTreatments added in serum-free medium to 96-well plates followed by the addition of yeasts, shaking at
37°C, and then counting phagocytosed cells.
fResults from growth of macrophages in chamber slides.
gSAP ex serum indicates SAP offered in serum.
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Only 10% to 40% of macrophages phagocytosed yeast (Fig. 2A). The morphology of
SAP-treated macrophages was noticeably different from that of control macrophages:
the former were smaller and more compact with rounded cell contours rather than
pseudopodal extensions. This may be an attribute of the immunological quiescence of
the cells due to SAP treatment (22, 23). A time course showed that SAP treatment of the
macrophages was rapid, with 90% inhibition of phagocytosis after 60 min of incuba-
tion with exogenously added SAP prior to the addition of yeasts (Fig. 2C). Because
mannose is an inhibitor of SAP binding to macrophages (24), a major saccharide found
in the cell wall of fungi, and the mannose receptor found on macrophages is
important in yeast phagocytosis, we tested the effect of D-mannose on the inter-
action of yeasts and macrophages. Phagocytosis of yeasts was inhibited by 78% in
the presence of 100 mM mannose (Table 1), implying involvement of the macro-
phage mannose receptor.
Serum or SAP treatment of yeast inhibits macrophage phagocytosis of yeast.
To determine whether incubation of yeast with serum affects macrophage phagocy-
FIG 2 Phagocytosis of yeast. (A) Macrophages in serum-free medium (pink cytoplasm, 40 m in diameter) and untreated C. albicans yeast cells (blue ovals,
2 to 3 m existing in singlets and doublets and multiples of the same). Many yeasts are phagocytosed by macrophages. Bar, 50 m. (Upper right) Close-up
of macrophage that has phagocytosed 15 yeast cells. Bar, 50 m. (B) Photomicrograph of macrophages pretreated with SAP. Note the round conformation of
the macrophages compared to those in panel A above. Bar, 50 m. (C) Phagocytosis of yeasts by macrophages preincubated in serum-free medium in the
presence or absence of SAP (30 g/ml). Results represent yeasts phagocytosed by 400 macrophages per time point. Results at zero and 15 min are not
signiﬁcantly different. The time points of 30, 60, and 120 min are signiﬁcantly different with P values of 0.05, 0.01, and 0.01, respectively. Medians are
depicted to show central tendency. Bars represent 95% conﬁdence limits, and signiﬁcance was determined by the Mann-Whitney U test.
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tosis of yeast, Candida albicans yeasts were incubated in normal human serum for 1 h,
washed, and then incubated with human macrophages. Compared with pretreatment
of the macrophages with SAP, serum treatment of the yeasts did not signiﬁcantly
increase binding of yeasts to the macrophages (Fig. 1D, bottom left). Nevertheless,
serum treatment of the yeasts decreased macrophage phagocytosis of yeast by 82%
(Fig. 1D, bottom right). This result is not signiﬁcantly different from the 86% inhibition
of phagocytosis following pretreatment of macrophages with SAP. The same phenom-
enon occurred with macrophages cultured on chamber slides (Table 1). In addition,
macrophage phagocytosis of yeast decreased by 62% when the yeast cells were
presoaked in puriﬁed SAP for 1 h in TBS-C (Table 1 and Fig. S1D). These results indicate
that pretreatment of yeast or macrophages with SAP profoundly inhibits macrophage
phagocytosis of yeast. The results were consistent for SAP added as a constituent of
serum or as puriﬁed SAP in buffer.
The combination of SAP and Candida increases expression of two macrophage
M2 markers. Macrophages change markers and physiology when exposed to different
external signals (25). We assessed the effects of SAP and yeasts on macrophage markers
associated with polarization: ICAM-1 (CD54), CD206, CD209, and the transcription
factors IRF4 and IRF5. All macrophages showed expression of CD45, demonstrating
their origin from the bone marrow (Fig. 3A). There were no signiﬁcant effects of
Candida, SAP, or serum on the percentage of cells expressing the two M1 markers
FIG 3 Expression of markers by macrophages. (A and B) Macrophages were incubated in serum-free
medium (control) or in serum-free medium plus the following: C. albicans alone; SAP alone; SAP and C.
albicans; or C. albicans yeast cells offered SAP in normal human serum. Results show the percentage of
macrophages staining for markers following different treatments. A bar within a colored box is the
median value, and the box represents the 95% conﬁdence intervals of values from four separate donors.
Values that are signiﬁcantly different (P 0.05) by Mann-Whitney U test are indicated by a bar and
asterisk.
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ICAM-1 and IRF5 (Fig. 3A). Examining the correlation between yeast phagocytosis and
marker expression, we observed that all macrophages that phagocytosed yeasts ex-
pressed ICAM-1. SAP and Candida plus SAP increased the percentage of cells expressing
the M2 marker CD206, and Candida plus SAP and serum-soaked Candida increased the
percentage of cells expressing IRF4 (Fig. 3B). SAP decreased the percentage of cells
expressing the M2 marker CD209 (Fig. 3B). Together, these results indicate that SAP and
Candida can affect some marker expression in macrophages.
Compared to Candida alone, SAP and Candida decrease accumulation of the
proinﬂammatory cytokine IFN- and increase accumulation of the anti-
inﬂammatory cytokine IL-10. Macrophage signaling through secreted cytokines is a
key event in innate and acquired immunity. Therefore, we assessed extracellular
cytokine accumulation in the presence of C. albicans yeasts and/or SAP. Macrophage
extracellular accumulation of IL-6, IFN-, TNF-, and IL-10 was increased by either
yeasts or SAP (Fig. 4). However, compared to SAP alone or yeast alone, combining SAP
and yeast decreased the accumulation of the inﬂammatory cytokine IFN- and in-
creased the anti-inﬂammatory cytokine IL-10 (Fig. 4). Extracellular IL-17A accumulation
was increased when yeasts were added to the cell culture, and SAP did not signiﬁcantly
affect the accumulation of this cytokine (Table 2).
SAP does not inhibit PMN phagocytosis of yeasts. Because PMNs are important
in cellular innate immunity, we examined what effect SAP has on PMN phagocytosis of
C. albicans. Human PMNs were pretreated with SAP (30 g/ml) for 60 min, and C.
albicans yeasts were then added in serum-free medium. After 30 min of coincubation,
there was no signiﬁcant effect of SAP on PMN phagocytosis of yeast, and this effect was
seen for both male and female donors (Fig. 5).
FIG 4 Cytokine secretion by macrophages after various treatments. The treatments were : macrophages in serum-free medium (Mac. Only), addition of C.
albicans to macrophages (Post Can.), addition of SAP only (post SAP Pre Can.), and pretreatment of macrophages with SAP (30 g/ml) followed by the addition
of C. albicans (Post SAP. Post Can.). Medians are plotted to show central tendencies with 95% conﬁdence intervals. Statistical signiﬁcance was determined by
Mann-Whitney U test and indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P  0.01.
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DISCUSSION
Results reported here may explain the highly attenuated inﬂammatory response in
infected tissue, a paradoxical feature of invasive fungal disease in humans (11, 13–16).
In several invasive fungal diseases, fungal cells in deep infections display surface
amyloid-like structures and are coated by the amyloid-binding SAP (11–13). We now
report that a consequence of SAP binding to fungi is the down-modulation of the
innate cellular immune response.
Human macrophages recognize fungal surface amyloid-like structures. Macro-
phages bind yeasts through lectin receptors, including the mannose receptor (MR)
(CD206) and DC-SIGN or CD209 (26, 27) to facilitate phagocytosis even when bacteria
or yeasts are unopsinized (27, 28). Our data reﬂect the involvement of CD206, because
phagocytosis was signiﬁcantly inhibited by the addition of D-mannose. Under the
conditions of our experiments, phagocytosis of yeasts was clearly related to the level of
surface amyloids present on the fungi, but how much occurs through CD206 or
DC-SIGN is unknown. Macrophages were largely indifferent to our laboratory strain of
S. cerevisiae which expresses very low background levels of the amyloidogenic proteins
Flo1 and Flo11 (29), and there was minimal phagocytosis of yeast expressing the
nonamyloidogenic Als5pV326N (19). In contrast, yeast cells expressing the wild-type
amyloidogenic sequence were phagocytosed at high levels. C. albicans yeast cells were
phagocytosed to an even higher degree, and these cells possess a higher level of
surface amyloid and a large number of potentially amyloidogenic adhesins (9, 10, 30).
Therefore, formation of amyloid-like nanodomains could activate phagocytosis by
clustering CD206 into high-avidity patches on the cell surface, as we have shown for
activation of fungal adhesins (9). Bacterial functional amyloids have frequently been
implicated as virulence factors in many diseases including involvement with innate
TABLE 2 IL-17A secretion by macrophages in response to different treatmentsa
Treatment
IL-17A
level
(pg/ml)b Signiﬁcancec
Macrophages only 1.1 0.1
Yeast cells added to macrophages 2.5 0.4 0.006
SAP (30 g/ml) added to macrophages 1.0 0.1 NS
SAP (30 g/ml)  yeast cells added to macrophages 3.7 0.3 0.002
aIL-17A secretion by macrophages in response to addition of SAP and/or yeasts for two replicates in each
experiment (three different experiments).
bValues are means  standard errors of the means from three experiments.
cSigniﬁcance was determined by Mann-Whitney U test. NS, not signiﬁcant.
FIG 5 Phagocytosis of C. albicans yeasts by human polymorphonuclear leukocytes (PMNs). Controls are
PMNs offered yeasts in serum-free medium; SAP treated are PMNs pretreated with SAP (30 g/ml),
washed, and offered yeasts in serum-free medium. Cells were from three females (F-1 to F-3) and two
males (M-1 and M-2). Medians are plotted to show central tendency with 95% conﬁdence levels. There
was no signiﬁcant difference with the Mann-Whitney U test between controls and SAP-pretreated PMNs
with respect to phagocytosis.
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immune cells (31). One example is the amyloid pilus of Mycobacterium tuberculosis that
facilitates invasion of macrophages (32), and SAP markedly reduces M. tuberculosis
phagocytosis (33). The phagocytosis of M. tuberculosis is similar to that of C. albicans,
i.e., both are engulfed within a phagolysosome, the difference is that the bacteria
persist in macrophages, whereas C. albicans is killed (34), or the fungus kills the
macrophage after shifting to hyphal morphology (35). Phagocytosis of M. tuberculosis
or Mycobacterium smegmatis in the presence of SAP also skews the macrophages
toward the “tolerant” M2c cell type, and this skew can be reduced in the presence of
small molecules that block SAP binding (36). Thus, in both microbes (M. tuberculosis and
C. albicans), SAP may bind to amyloid-like structures and lead to increased microbe
survival and propagation.
SAP binding to fungi is dependent upon fungal expression of functional
amyloid and is antiphagocytic. The importance of SAP binding to bacteria and the
implications this phenomenon might have on host defenses were reported years ago
(5), but they have not been pursued systematically. It was proposed that binding of SAP
to beads is opsonic, but SAP binding to bacteria protects the bacteria from degradation
and is antiopsonic and anti-immunogenic (5, 37). Binding of SAP to C. albicansmay give
rise to similar antiphagocytic and anti-inﬂammatory effects. Wild-type C. albicans
expresses a number of cell surface functional amyloids, the best studied is Als5p (19),
a member of a family of amyloidogenic adhesive proteins variably expressed on the cell
surface (7). In invasive candidiasis, SAP binds to functional amyloid nanodomains on the
surface of the fungi. The consequences of this binding include inhibition of macro-
phage phagocytosis and reduction in secretion of inﬂammatory cytokines. Thus, human
SAP, a soluble pentraxin that binds avidly to pathological human amyloids (38), also
binds to C. albicans functional amyloids.
The presence of functional amyloids explains the binding of SAP to S. cerevisiae-
Als5p compared to S. cerevisiae-EV and S. cerevisiae-Als5pV326N, which has little surface
amyloid. The SAP binding capacities of the yeasts were C. albicans  S. cerevisiae-
Als5pWT  S. cerevisiae-Als5pV326N  S. cerevisiae-EV, an order consistent with the
ability of yeasts to form amyloid-like surface nanodomains (9, 10, 39). The low levels of
SAP binding could be due to residual surface amyloids (39) or exposure of phospho-
ethanolamine and/or phosphocholine in the yeast cell wall, as they are ligands of SAP
(40–42). It is possible that SAP binding to microbial amyloid is common: SAP binding
to surface proteins of Neisseria meningitidis was investigated, and two of the three
identiﬁed SAP-binding proteins, NMB0667 and NMB201 (43), have multiple regions
with high amyloid potential, like many fungal adhesins (data not shown).
SAP coating of fungi markedly inhibited phagocytosis, with a corresponding in-
crease in C. albicans bound but not engulfed. The results were similar whether the
yeasts or macrophages were treated with puriﬁed SAP or SAP was offered to yeasts in
normal serum, and the effects of SAP on macrophage phagocytosis were detected
within minutes. This SAP binding may result from fungal exploitation of SAP’s role as
an immunomodulatory molecule, rather than as a human adaptation to infection.
Fungal surface amyloids have evolved as components of bioﬁlms, and SAP binding may
be a fortuitous consequence (8, 9, 11, 23, 38).
SAP is anti-inﬂammatory. The consequences of SAP binding included reduction in
accumulation of proinﬂammatory cytokines and an increase in accumulation of anti-
inﬂammatory IL-10. IL-10 secretion by macrophages increased in response to SAP
treatment of the macrophages or the yeast cells. These results conﬁrm well-established
anti-inﬂammatory properties of SAP, which has been previously shown to reduce
neutrophil adhesion (44, 45), to inhibit maturation of monocytes to ﬁbrocytes in tissue
(44), and to coat cell debris which is scavenged by macrophages (37). Accordingly, SAP
also directs macrophage differentiation toward resolving macrophage class M2c (22).
The anti-inﬂammatory effect is dependent upon the production of IL-10 which follows
SAP binding to DC-SIGN (46).
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Our incubation of SAP with macrophages in ﬂuid phase or bound to C. albicans
yeasts led to changes in macrophage surface antigen expression. Markers of the M1
phenotype (ICAM-1, IFR5) were unchanged, whereas IRF4 and the M2 marker pheno-
type CD206 increased. Detection of CD209 (DC-SIGN) decreased with exposure to SAP.
CD209 is a macrophage receptor that may account for up 30% of C. albicans phago-
cytosis (28), and SAP binding to DC-SIGN leads to increased IL-10 secretion that
potentiates an anti-inﬂammatory response (46). Detection of DC-SIGN with antibodies
was lower on the macrophages incubated with SAP, either due to downregulation of
the receptor, or perhaps the antibody binding site was masked by the binding of SAP
to the receptor. These results are in conformity with the anti-inﬂammatory properties
of SAP (23) and along with the changes in cytokine expression due to SAP, may help
to downregulate the response of the innate immune system.
However, CD206 (MR receptor) was moderately upregulated in the presence of SAP.
Candida binding to MR (CD206) stimulates macrophages to secrete the proinﬂamma-
tory cytokine IL-17 (47), a feature we observed. The amount of IL-17 secreted was not
altered by incubating the macrophages with SAP, but it was the only proinﬂammatory
cytokine observed to increase in the presence of SAP and yeasts. Thus, we ﬁnd that for
invasive candidiasis, the presence of SAP on macrophages or yeasts, shifted the
macrophage response toward an anti-inﬂammatory outcome.
PMNs and SAP. We did not ﬁnd SAP-dependent differences in neutrophil phago-
cytosis of C. albicans. SAP reduces neutrophil adhesion and spreading (23), and this may
have led to the very small numbers of yeasts phagocytosed.
Conclusion. SAP binds to C. albicans fungal cell surface functional amyloid, a
structure recognized by macrophages. SAP bound to fungal surfaces is antiphagocytic
and anti-inﬂammatory, reducing phagocytosis of fungi and increasing IL-10 secretion
(Fig. 6). Although the question remains open whether SAP binding to fungi helps the
host or the pathogen (5, 48), it appears from our work that SAP-coated yeasts are either
FIG 6 Figurative rendition of important ﬁndings of this investigation involving human macrophage-SAP-
Candida albicans yeast interactions. (Left) The macrophage is a control macrophage (cultured in serum-free
medium) and C. albicans yeasts added to it in serum-free medium. The cell secretes numerous cytokines
and phagocytoses yeasts in great numbers. (Top right) The macrophage is cultured like the control
macrophage, but the C. albicans yeasts are soaked in normal human serum or in puriﬁed SAP for an hour
before addition to the macrophage, allowing SAP to bind to the fungal functional amyloid. Phagocytosis
is reduced 80%. (Bottom right) The macrophage is cultured identically to the control macrophage except
that it is incubated with SAP (30 g/ml) for 1 h before C. albicans yeasts are added. Like the macrophage
above it, there is a 80% reduction in phagocytosis of yeast cells, but only IL-10 and IL-17A are secreted
in increased amounts. After SAP treatment, the macrophages were more rounded in their overall shape, a
reﬂection of their quiescence.
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masked from the innate immune system or, upon contact with host cells, dampen the
immune response.
MATERIALS AND METHODS
Macrophages. Human macrophages were isolated from whole blood using the SepMate-50 system
(Stemcell Technologies, Seattle, WA) and following a University of Arizona IRB-approved protocol with
written consent from the donors. After isolation, the cells were cryopreserved gradually with a controlled
rate freezer. For experimental use, cryopreserved peripheral blood mononuclear cells (PBMCs) from
normal (healthy) adult controls were placed in complete RPMI (RPMI, 10% fetal bovine serum, penicillin/
streptomycin, and DNase [3 ng/ml]) and thawed to 37°C. Cells were collected by centrifugation at
500 g for 6 min, resuspended in X-VIVO-15 (Lonza, Walkersville, MD), a serum-free medium, plated into
96-well plates (Fisher Scientiﬁc) (105 cells in 100 l medium/well), and placed in an incubator overnight
at 37°C with 5% CO2. The following day PBMCs were washed with serum-free medium and resuspended
in fresh medium, human MCSF (Sigma-Aldrich, St. Louis, MO) was added to each well (1 ng/ml), and cells
were incubated for 5 days at 37°C with 5% CO2. Experiments were also carried out in four-well slide
chambers (Bio Express, Visalia, CA) with the same medium and additives and 200 l/well. Slide chambers
allowed for better photomicroscopy of the macrophage-fungus interactions.
Fungi. Two Candida albicans strains were used in this study, one a clinical isolate (Banner University
Medical Center, Tucson, AZ) and the other, a quality control strain from the Clinical and Laboratory
Standards Institute (Wayne, PA). There was no difference in results with the two strains. The two strains
were maintained on YPD agar (RPI, Mount Pleasant, IL). For experiments, a loopful of fungi was added
to 5 ml YPD broth (Life Technologies Corp., Carlsbad, CA) and incubated overnight at 26°C with shaking.
After 24 h, the yeasts were collected by centrifugation at 1,200 g for 5 min, resuspended, and washed
thoroughly in Tris-buffered saline with 2 mM Ca2 (TBS-C). This was repeated three times, and cells were
then resuspended to 109 cells/ml in TBS-C and used as described below. Saccharomyces cerevisiae strains
Als5p, V326N, and EV (background W303-1B) expressing variations of the C. albicans Als5p protein (19)
were under a galactose promoter; therefore, the strains were grown in CSM-Trp galactose broth plus
adenine (Thermo Fisher, Waltham, MA). Yeast strains were maintained on agar with the same medium.
S. cerevisiae strains were cultured in CSM-Trp galactose broth plus adenine at 26°C for 48 h, and washed
with TBS-C as described above.
Macrophage-yeast interactions. Wells containing 5-day-old macrophages in chamber slides or
96-well plates were washed with serum-free medium, and 100 l of fresh serum-free medium and 1 l
containing 106 previously washed yeasts suspended in TBS-C were added to each well. For other
experiments, alongside the addition of C. albicans alone to wells or chambers, C. albicans was also
incubated in 100% normal human male AB serum (Innovative Research, Novi, MI) or SAP (Millipore,
Temecula, CA) at 30 g/ml for 1 h at 4°C, washed with TBS-C, resuspended in serum-free medium, and
added to wells or chambers. The cocultures were incubated at 37°C on a rocking shaker for 30 min. The
yeast/macrophage ratio varied from 100 to 10:1. A 30-min incubation of yeasts with macrophages was
employed to minimize the number of yeasts forming germ tubes. Following incubation of yeasts with
macrophages, the wells were washed gently three times with TBS-C, and the wells or slides were stained
with Wright-Giemsa. Stained wells and slides were observed by light microscopy, and a binding index
(number of yeasts bound/50 macrophages/well or chamber) and a phagocytic index (number of yeasts
phagocytosed/50 macrophages/well or chamber) was determined for each replicate in 96 wells or
chamber slides (49). Each assay was repeated a minimum of three times. More than 30 different cell
donors were used, and there was a remarkable consistency in the numbers of yeast cells phagocytosed
per macrophage whether the cells were from male or female donors or from one week to the next with
the same donor.
SAP and other additives. Human SAP or buffer-exchanged SAP (as described by Shao et al. [22]) in
serum-free medium was added to wells to a ﬁnal concentration of 30 g/ml (the normal level in human
serum). Other additives included CRP (Fitzgerald Industries, Acton, MA), D-mannose (Sigma-Aldrich),
EDTA (Sigma-Aldrich), normal human male AB serum (Innovative Research), or bovine serum albumin
(BSA) (Sigma-Aldrich) as described in the Results.
Flow cytometry. Fungi were cultured overnight (C. albicans) or for 48 h (S. cerevisiae) as described
above, collected by centrifugation, and resuspended in TBS-C. Cells were incubated in undiluted normal
human male AB serum or in TBS-C with 30 g/ml SAP for 1 h at 4°C, washed three times by
centrifugation, and resuspended in TBS-C. Cells were then incubated in TBS-C with 1:100 rabbit
polyclonal anti-human SAP antibodies (PA5-24171; Invitrogen), or 1:100 anti-human CRP mouse mono-
clonal antibodies (MABF1070; clone 2A8.1, EMD-Millipore Corporation) for 30 min at 4°C. Yeasts were
then washed three times and incubated with 1:200 ﬂuorescein-labeled goat anti-rabbit or anti-
mouse antibody (Invitrogen) for 30 min, washed three times, and resuspended in TBS. Fluorescence
of cells was read on a BD LSR II ﬂow cytometer (BD Biosciences, San Jose, CA) and then analyzed
using Flowjo version 10.
Determination of macrophage antigen expression by immunocytochemistry. Macrophages
were cultured in serum-free medium in 96-well plates as described above. After 5 days, the medium was
replaced with the following: fresh serum-free medium for 30 or 60 min (control); serum-free medium
plus C. albicans yeasts for 30 min; serum-free medium plus SAP (30 g/ml) for 1 h; serum-free medium
plus SAP (30 g/ml) for 1 h followed by C. albicans yeasts for 30 min; or serum-free medium with C.
albicans yeasts that had been soaked in normal human serum at 4°C for 30 min. For staining,
macrophages were ﬁxed with acetone for 15 min and air dried for 15 min, and nonspeciﬁc binding was
blocked by incubation in PBS containing 4% BSA (PBS-BSA) for 60 min (22). Wells were then incubated
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with 5 g/ml primary antibodies in PBS-BSA for 60 min as previously described (38). Isotype-matched
irrelevant antibodies were used as controls. Antibodies from BioLegend (San Diego, CA) were anti-CD45,
mouse IgG1, (catalog no. 304002), anti-CD54 (ICAM), mouse IgG1 (catalog no. 353102), and anti-CD206,
mouse IgG1 (catalog no. 321102). Antibodies from Abcam (Cambridge, UK) were anti-CD209, mouse IgG1
(ab89186), anti-IRF5, rabbit monoclonal (EPR6094), and anti-IFR4, rabbit monoclonal (EP5699). Irrelevant
mouse IgG1 (BioLegend) or rabbit polyclonal antibodies (R&D Systems, Minneapolis, MN) at 5 g/ml in
PBS-BSA were used as controls. Primary antibodies were detected with either biotinylated donkey F(ab=)2
anti-mouse IgG or biotinylated donkey F(ab=)2 anti-rabbit IgG (all cross-adsorbed against human Ig;
Jackson ImmunoResearch, West Grove, PA). All secondary antibodies were used at 1 g/ml in PBS-BSA
for 30 min. Biotinylated antibodies were detected by a 1/500 dilution of ExtrAvidin alkaline phosphatase
(Vector Laboratories, Burlingame, CA) in PBS-BSA. Staining was developed with the Vector Red Alkaline
Phosphatase kit (Vector Laboratories) for 5 to 7 min and then counterstained with Gill’s hematoxylin
number 3 (Sigma-Aldrich) following the manufacturer’s directions. Macrophages were identiﬁed as 15- to
40-m-diameter cells with a large nucleus and pronounced cytoplasm. Cells were washed, dried, and
later rehydrated with water, and cells were counted microscopically. There were six wells of macrophages
for each antibody, and the experiment was repeated twice (100 macrophages were counted per well).
Polymorphonuclear leukocyte phagocytosis of yeasts. Blood samples from ﬁve healthy adult
volunteers (three women and two men) were drawn into vacutainer tubes containing EDTA (Fisher
Scientiﬁc, Waltham, MA) with written approval following a University of Arizona IRB-approved protocol.
The blood was layered onto Polymorphoprep (Thermo Fisher) in a polypropylene tube and processed
according to the manufacturer’s directions and centrifuged at 500 g for 30 min. Isolated polymorpho-
nuclear leukocytes (PMNs) were washed with TBS-C by centrifugation at 500 g for 5 min twice and
resuspended in TBS-C to 107cells/ml. Then 100 l was placed in each well of 96-well plates, incubated
with 30 g/ml SAP or without SAP for 1 h at 37°C, and washed with buffer. Yeasts were added at a ratio
of 100 to 10 yeasts/PMN or yeasts incubated in serum for 1 h were added to PMNs and incubated for 30
min at 37°C with shaking. The cells were washed three times with TBS-C and stained with Wright-Giemsa.
The number of yeasts phagocytosed per 50 PMNs was determined by microscopy.
Cytokine measurements. Macrophages were cultured in serum-free medium as described above in
96-well plates. After 5 days, the medium was replaced with the following: fresh serum-free medium;
serum-free medium plus 30 g/ml SAP (1 h); serum-free medium with C. albicans yeasts; or serum
free-medium plus SAP, followed by addition of yeasts for 30 min. Media were aspirated from the wells
at various time points and stored at 20°C. Thawed media were assayed for human IL-6, TNF-, IFN-,
IL-10, and IL-17A homodimers using Ready-SET-Go ELISA kits following the manufacturer’s protocols
(Invitrogen).
Statistics. All population totals were graphed using median values and 95% conﬁdence intervals or
means with standard errors. An unpaired, nonparametric Mann-Whitney test or a basic unpaired t test
was used to determine statistical signiﬁcance between different populations and treatment conditions.
Medians are shown in some graphs to show the central tendency. Software used was Prism version 7
(Graphpad, San Diego, CA).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
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